brentuximab vedotin (Adcetris)
Jump to navigation
Jump to search
Structure
- approximate molecular weight of 153 kDa
- the drug consists of 3 components
- chimeric IgG1 antibody cAC10, specific for human CD30
- microtubule disrupting agent MMAE
- a protease-cleavable linker that covalently attaches MMAE to cAC10
Indications
- treatment of relapsed or refractory Hodgkin's lymphoma
- treatment of stage III/IV Hodgkin's lymphoma, in combination with doxorubicin, vinblastine, & dacarbazine
- systemic anaplastic large cell lymphoma with treatment failure
Dosage
- 1.8 mg/kg infused over 30 minutes every 3 weeks
- maximum of 16 cycles
Lyophilyzed powder in single use vials
Adverse effects
- hematologic
- neurologic
- general
- infections
- gastrointestinal
- skin
- respiratory
- cough
- dyspnea
- oropharyngeal
- pulmonary toxicity
- musculoskeletal
- arthralgia
- myalgia
- back pain
- pain in extremity
- muscle spasms
- psychiatric
Mechanism of action
- antibody-drug conjugate that combines the monoclonal antibody brentuximab & the antimitotic agent monomethyl auristatin (vedotin), thus targeting CD30 receptors on tumor cells before release of the toxic chemotherapeutic agent
More general terms
Component of
References
- ↑ Waknine Y Medscape Oncology FDA Approves Brentuximab for Refractory Lymphomas http://www.medscape.com/viewarticle/748353
- ↑ National Cancer Institute FDA Approval for Brentuximab Vedotin http://www.cancer.gov/cancertopics/druginfo/fda-brentuximabvedotin
- ↑ 3.0 3.1 FDA MedWatch: 01/13/2012 Adcetris (brentuximab vedotin): Drug Safety Communication - Progressive Multifocal Leukoencephalopathy and Pulmonary Toxicity http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm287710.htm
- ↑ MedPage Today Staff FDA OKs Adcetris for Untreated Hodgkin's Brentuximab plus chemo led to better 2-year PFS in ECHELON-1 trial. MedPage Today. March 20, 2018 https://www.medpagetoday.com/hematologyoncology/lymphoma/71884
- ↑ Adcetris http://www.rxlist.com/adcetris-drug.htm